Malaria Adenoviral Vaccine

疟疾腺病毒疫苗

• 批准号: G0502018/1
• 负责人: Adrian Hill
• 金额: $ 82.52万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2006
• 资助国家: 英国
• 起止时间: 2006 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0502018%2F1
• 关键词: Malaria; Adenoviral; Vaccine

Malaria is one of the greatest causes of infectious mortality globally but no vaccine is available. For over ten years it has been known that a particular type of immune response can impart strong protection against malaria. This entails a cellular immune response by killer T cells against the malaria parasite growing in liver cells. A new type of attenuated safe virus that can carry malaria genes has been developed as a vaccine that can induce these killer cells very strongly and protect against rodent malaria. We shall generate a vaccine of this type and test its ability to protect vaccinated individuals against malaria infection. If successful this approach could help develop vaccines of a similar type against a variety of other diseases.

疟疾是全球感染性死亡的最大原因之一，但没有疫苗可用。十多年来，人们已经知道一种特定类型的免疫反应可以对疟疾产生强有力的保护作用。这需要杀伤性T细胞对生长在肝细胞中的疟原虫产生细胞免疫反应。一种可以携带疟疾基因的新型减毒安全病毒已经被开发出来，作为一种疫苗，可以非常强烈地诱导这些杀伤细胞，防止啮齿动物疟疾。我们将生产这种类型的疫苗，并测试其保护接种疫苗的个人免受疟疾感染的能力。如果成功，这种方法可以帮助开发针对各种其他疾病的类似类型的疫苗。